These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6057363)

  • 21. [Plasma cell proliferation, benign and malignant. The clinical picture caused by the neoplastic plasma cell (author's transl)].
    Waldenström JG
    Cas Lek Cesk; 1975 Aug; 114(34-35):1037-40. PubMed ID: 1175191
    [No Abstract]   [Full Text] [Related]  

  • 22. On the conversion of 3-hydroxyanthranilic acid to quinolinic acid in presence of hepatic tissue of rats affected by Oberling's myeloma in the leukemic phase.
    QUAGLIARIELLO E; AURICCHIO S; RINALDI E; VIOLANTE A
    Clin Chim Acta; 1958 Jul; 3(4):381-3. PubMed ID: 13561506
    [No Abstract]   [Full Text] [Related]  

  • 23. The increase of CD5LOW+NK cells in patients with multiple myeloma and plasmacytoma.
    Ishiyama T; Watanabe K; Fukuchi K; Yajima K; Koike M; Tomoyasu S; Tsuruoka N
    Anticancer Res; 1994; 14(2B):725-30. PubMed ID: 7516640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low IgE monoclonal gammopathy level in serum highlights 20-yr survival in a case of IgE multiple myeloma.
    Hayes MJ; Carey JL; Krauss JC; Hedstrom DL; Gulbranson RL; Keren DF
    Eur J Haematol; 2007 Apr; 78(4):353-7. PubMed ID: 17378894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Soluble syndecan-1 levels in different plasma cell dyscrasias].
    Jánosi J; Sebestyén A; Mikala G; Petö M; Jákó J; Domján G; Németh J; Kis Z; Kopper L; Vályi-Nagy I
    Orv Hetil; 2005 Jan; 146(4):165-8. PubMed ID: 15751511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the effect of DPN on the conversion of 3-hydroxyanthranilic acid to quinolinic acid in presence of hepatic tissue of rats affected by Oberling's myeloma in the leukemic phase.
    QUAGLIARIELLO E; AURICCHIO S; RINALDI E; VIOLANTE A
    Clin Chim Acta; 1958 Sep; 3(5):441-2. PubMed ID: 13585618
    [No Abstract]   [Full Text] [Related]  

  • 27. [Development of an extramedullary plasmacytoma despite disappearing M protein in multiple myeloma by bortezomib treatment].
    Koiso H; Tahara K; Osaki Y; Mawatari M; Sekigami T; Yokohama A; Saitoh T; Uchiumi H; Handa H; Tsukamoto N; Karasawa M; Nojima Y; Murakami H
    Rinsho Ketsueki; 2009 Feb; 50(2):78-82. PubMed ID: 19265298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasmocytoma. Report of a case.
    Chan KP; Tam CS
    Cancer; 1969 Mar; 23(3):694-8. PubMed ID: 5766507
    [No Abstract]   [Full Text] [Related]  

  • 29. Serum protein electrophoresis.
    Neilley L
    Nurse Pract; 1982 May; 7(5):35-42. PubMed ID: 7099505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [THE SIGNIFICANCE OF PAPER ELECTROPHORESIS SERUM PROTEIN IN THE DIAGNOSIS OF BONE NEOPLASMS].
    FERNBACH J; MASSANYI L; PINTER J
    Orv Hetil; 1963 Sep; 104():1646-9. PubMed ID: 14054563
    [No Abstract]   [Full Text] [Related]  

  • 31. Systemic matrix metalloproteinase-9 (MMP-9) levels as prognostic indexes of bone disease in patients with multiple myeloma.
    Demacq C; Montenegro MF
    Clin Chem Lab Med; 2006; 44(2):232; author reply 233. PubMed ID: 16475914
    [No Abstract]   [Full Text] [Related]  

  • 32. [Bisalbuminemia. Review and observations on the acquired form in a patient with myeloma].
    Pola V; Tichý M
    Vnitr Lek; 1984 Aug; 30(8):813-21. PubMed ID: 6390938
    [No Abstract]   [Full Text] [Related]  

  • 33. [Osseous myeloma].
    Lejeune E
    Lyon Chir; 1965 Nov; 61(6):921-5. PubMed ID: 5859393
    [No Abstract]   [Full Text] [Related]  

  • 34. Multifocal extramedullary plasmacytoma with paraproteinemia, pleural involvement and retroperitoneal lymphadenopathy: an uncommon pattern of relapse of solitary osseous plasmacytoma.
    Vassou A; Alymara V; Agelis E; Stefanaki S; Bourantas KL
    Ann Hematol; 2006 May; 85(5):335-6. PubMed ID: 16496148
    [No Abstract]   [Full Text] [Related]  

  • 35. [Resolution of an electrophoretic peak in a case of multiple myeloma].
    SANTAMARIA R; VERGINE A
    Boll Soc Ital Biol Sper; 1954 Jun; 30(6):604-6. PubMed ID: 14351372
    [No Abstract]   [Full Text] [Related]  

  • 36. Osteocalcin is not a marker of progress in multiple myeloma. Le Groupe d'Etude et de Recherche sur le Myélome (GERM).
    Mejjad O; Le Loët X; Basuyau JP; Ménard JF; Jego P; Grisot C; Daragon A; Grosbois B; Euller-Ziegler L; Monconduit M
    Eur J Haematol; 1996; 56(1-2):30-4. PubMed ID: 8599990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple myeloma in chronic kidney disease. Utility of discretionary screening using serum electrophoresis.
    Doyle A; Soutar R; Geddes CC
    Nephron Clin Pract; 2009; 111(1):c7-11. PubMed ID: 19033691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Experience with a dynamic study of protein fractions in the blood in multiple myeloma (electrophoretic data)].
    ALEKSEEV GA; RYZHKOVA NP
    Probl Gematol Pereliv Krovi; 1962 Oct; 7():3-11. PubMed ID: 14011876
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pleural plasmacytoma].
    Swaelens A; Prignot J; Meersseman F
    Acta Tuberc Pneumol Belg; 1971; 62(2):105-12. PubMed ID: 5112899
    [No Abstract]   [Full Text] [Related]  

  • 40. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
    International Myeloma Working Group
    Br J Haematol; 2003 Jun; 121(5):749-57. PubMed ID: 12780789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.